Updated on 2025/06/30

Information

 

写真a

 
SAKODA TEPPEI
 
Organization
Kyushu University Hospital Hematology, Oncology & Cardiovascular medicine Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Profile
病棟・外来にて診療業務への従事の傍ら、自らの急性骨髄性白血病に関する研究の他、病棟実習の学生への指導、大学院生への研究指導を行っている。
External link

Research Interests・Research Keywords

  • Research theme: Elucidation of the mechanism for therapy-resistance in residual acute myeloid leukemia stem cells at remission phase

    Keyword: acute myeloid leukemia, leukemia stem cell, minimal residual disease

    Research period: 2021.4 - 2024.3

Papers

  • KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML

    Zou, J; Kinosada, H; Takayanagi, SI; Ishii, T; Amano, T; Nihira, K; Kanie, S; Adachi, M; Tahara, H; Sakoda, T; Kikushige, Y; Akashi, K; Satou, H

    LEUKEMIA   2025.5   ISSN:0887-6924 eISSN:1476-5551

     More details

    Language:English   Publisher:Leukemia  

    Acute myeloid leukemia (AML) is a common hematopoietic malignancy with high recurrence rates, and there is an urgent need for new therapeutic agents. T-cell immunoglobulin mucin-3 (TIM-3) is expressed on the surface of both LSCs and blasts in most AML patients, but not in normal hematopoietic stem cells (HSCs). We have developed KK2845, an antibody drug conjugate (ADC) that consists of an anti-TIM-3 fully human IgG1 antibody, a valine-alanine linker and a highly potent DNA cross-linking pyrrolobenzodiazepine (PBD) dimer SG3199. KK2845 exhibited potent cytotoxicity against AML cells both in vitro and in vivo. The cytotoxicity against AML cells was almost comparable between KK2845 and CD33-ADC, an anti-CD33 antibody conjugated with PBD dimer that has shown high remission rates in clinical studies. In addition to the cytotoxicity depending on PBD dimer, KK2845 also showed potent antibody-dependent cell cytotoxicity (ADCC) activity against AML cells. KK2845 showed less cytotoxicity against human normal bone marrow cells than CD33-ADC. The pharmacokinetics of KK2845 in cynomolgus monkey after intravenous infusion demonstrated a favorable profile. Taken together, these data suggest that KK2845 could be a novel ADC therapeutic in AML.

    DOI: 10.1038/s41375-025-02642-2

    Web of Science

    Scopus

    PubMed

  • Objective quantification of pre-CAR-T EEG abnormalities for ICANS prognosis: insights from GTE scoring

    Nakagaki, H; Yamauchi, T; Mukaino, T; Sakata, A; Watanabe, E; Watanabe, M; Ishihara, D; Imanaga, H; Sasaki, K; Sakoda, T; Jinnouchi, F; Miyawaki, K; Shima, T; Kikushige, Y; Mori, Y; Hotta, T; Kunisaki, Y; Shigeto, H; Isobe, N; Akashi, K; Kato, K

    BONE MARROW TRANSPLANTATION   2025.4   ISSN:0268-3369 eISSN:1476-5365

     More details

    Language:English   Publisher:Bone Marrow Transplantation  

    DOI: 10.1038/s41409-025-02616-z

    Web of Science

    Scopus

    PubMed

  • Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of <i>PML::RARα</i>

    Minami, M; Sakoda, T; Kawano, G; Kochi, Y; Sasaki, K; Sugio, T; Jinnouchi, F; Miyawaki, K; Kunisaki, Y; Kato, K; Miyamoto, T; Akashi, K; Kikushige, Y

    LEUKEMIA   39 ( 4 )   844 - 853   2025.4   ISSN:0887-6924 eISSN:1476-5551

     More details

    Language:English   Publisher:Leukemia  

    Leukemic stem cells (LSCs) of acute myeloid leukemia (AML) can be enriched in the CD34<sup>+</sup>CD38<sup>-</sup> fraction and reconstitute human AML in vivo. However, in acute promyelocytic leukemia (APL), which constitutes 10% of all AML cases and is driven by promyelocytic leukemia-retinoic acid receptor alpha (PML::RARα) fusion genes, the presence of LSCs has long been unidentified because of the difficulty in efficient reconstitution of human APL in vivo. Herein, we show that LSCs of the short-type isoform APL, a subtype of APL defined by different breakpoints of the PML gene, concentrate in the CD34<sup>+</sup>CD38<sup>−</sup> fraction and express T cell immunoglobulin mucin-3 (TIM-3). Short-type APL cells exhibited distinct gene expression signatures, including LSC-related genes, compared to the other types of APL. Moreover, CD34<sup>+</sup>CD38<sup>−</sup>TIM-3<sup>+</sup> short-type APL cells efficiently reconstituted human APL in xenograft models with high penetration, whereas CD34<sup>−</sup> differentiated APL cells did not. Furthermore, CD34<sup>+</sup>CD38<sup>−</sup>TIM-3<sup>+</sup> short-type APL cells reconstituted leukemia cells after serial transplantation. Thus, short-type APL was hierarchically organized by self-renewing APL-LSCs. The identification of LSCs in a subset of APL and establishment of an efficient patient-derived xenograft model may contribute to further understanding the APL leukemogenesis and devise individual treatments for the eradication of APL LSCs.

    DOI: 10.1038/s41375-025-02530-9

    Web of Science

    Scopus

    PubMed

  • Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy

    Nomiyama, T; Setoyama, D; Yamanaka, I; Shimo, M; Miyawaki, K; Yamauchi, T; Jinnouchi, F; Sakoda, T; Sasaki, K; Shima, T; Kikushige, Y; Mori, Y; Akashi, K; Kato, K; Kunisaki, Y

    LEUKEMIA   39 ( 4 )   983 - 987   2025.4   ISSN:0887-6924 eISSN:1476-5551

     More details

    Language:English   Publisher:Leukemia  

    DOI: 10.1038/s41375-025-02541-6

    Web of Science

    Scopus

    PubMed

  • Identification of the ammonia detoxication pathway as a crucial metabolic mechanism in acute myeloid leukemia

    Ishihara, D; Kikushige, Y; Sakoda, T; Miyamoto, T; Soga, T; Akashi, K

    CANCER SCIENCE   116   1458 - 1458   2025.1   ISSN:1347-9032 eISSN:1349-7006

     More details

  • TIM-3 marks residual acute myeloid leukemia stem cells responsible for relapse after allo-SCT

    Sakoda, T; Kikushige, Y; Miyamoto, T; Akashi, K

    CANCER SCIENCE   116   1033 - 1033   2025.1   ISSN:1347-9032 eISSN:1349-7006

     More details

  • TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation

    Sakoda, T; Kikushige, Y; Irifune, H; Kawano, G; Harada, T; Semba, Y; Hayashi, M; Shima, T; Mori, Y; Eto, T; Kamimura, T; Iwasaki, H; Ogawa, R; Yoshimoto, G; Kato, K; Maeda, T; Miyamoto, T; Akashi, K

    CANCER SCIENCE   116 ( 3 )   698 - 709   2024.12   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:English   Publisher:Cancer Science  

    In this study, we investigated the measurable residual leukemic stem cell (MR-LSC) population after allogeneic stem cell transplantation (allo-SCT) for high-risk acute myeloid leukemia (AML), utilizing T-cell immunoglobulin mucin-3 (TIM-3) expression as a functional marker of AML leukemic stem cells (LSCs). Analysis of the CD34<sup>+</sup>CD38<sup>−</sup> fraction of bone marrow cells immediately after achievement of engraftment revealed the presence of both TIM-3<sup>+</sup>LSCs and TIM-3<sup>−</sup> donor hematopoietic stem cells (HSCs) at varying ratios. Genetic analysis confirmed that TIM-3<sup>+</sup> cells harbored patient-specific mutations identical to those found in AML clones, whereas TIM-3<sup>−</sup> cells did not, indicating that TIM-3<sup>+</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells represent residual AML LSCs. In 92 allo-SCT occasions involving 83 AML patients, we enumerated the frequencies of TIM-3<sup>+</sup>LSCs immediately after achieving hematologic complete remission with complete donor cell chimerism. Notably, only 22.2% of patients who achieved a TIM-3<sup>+</sup>MR-LSC<sup>low</sup> status (<60%) experienced relapse, with a median event-free survival (EFS) of 1581 days (median follow-up duration was 2177 days among event-free survivors). Conversely, 87.5% of patients with TIM-3<sup>+</sup>MR-LSC<sup>int/high</sup> (≥60%) relapsed, with a median EFS of 140.5 days. Furthermore, MR-LSC status emerged as a significant independent risk factor for relapse (hazard ratio, 8.56; p < 0.0001), surpassing the impact of patient disease status prior to allo-SCT, including failure to achieve complete remission (hazard ratio, 1.98; p = 0.048). These findings suggest that evaluating TIM-3<sup>+</sup> MR-LSCs immediately after engraftment, which reflects the competitive reconstitution of residual TIM-3<sup>+</sup> LSCs and donor HSCs, may be valuable for predicting outcomes in AML patients undergoing allo-SCT.

    DOI: 10.1111/cas.16431

    Web of Science

    Scopus

    PubMed

  • Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans

    Nakagaki, H; Yamauchi, T; Mukaino, T; Sakata, A; Watanabe, E; Watanabe, M; Ishihara, D; Imanaga, H; Sasaki, K; Sakoda, T; Jinnouchi, F; Miyawaki, K; Shima, T; Kikushige, Y; Mori, Y; Kunisaki, Y; Hotta, T; Shigeto, H; Isobe, N; Akashi, K; Kato, K

    BLOOD   144   2081 - 2082   2024.11   ISSN:0006-4971 eISSN:1528-0020

  • Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism

    Hatakeyama, K; Kikushige, Y; Ishihara, D; Yamamoto, S; Kawano, G; Tochigi, T; Miyamoto, T; Sakoda, T; Christoforou, A; Kunisaki, Y; Fukata, M; Kato, K; Ito, T; Handa, H; Akashi, K

    BLOOD ADVANCES   8 ( 3 )   785 - 796   2024.2   ISSN:2473-9529 eISSN:2473-9537

     More details

    Language:English   Publisher:Blood Advances  

    Immunomodulatory drugs (IMiDs) are key drugs for treating multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the interaction between cell-specific substrates and cereblon, a substrate receptor of the E3 ubiquitin ligase complex. Thus, identification of cell-specific substrates is important for understanding the effects of IMiDs. IMiDs increase the risk of thromboembolism, which sometimes results in fatal clinical outcomes. In this study, we sought to clarify the molecular mechanisms underlying IMiDs-induced thrombosis. We investigated cereblon substrates in human megakaryocytes using liquid chromatography–mass spectrometry and found that thrombospondin-1 (THBS-1), which is an inhibitor of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, functions as an endogenous substrate in human megakaryocytes. IMiDs inhibited the proteasomal degradation of THBS-1 by impairing the recruitment of cereblon to THBS-1, leading to aberrant accumulation of THBS-1. We observed a significant increase in THBS-1 in peripheral blood mononuclear cells as well as larger von Willebrand factor multimers in the plasma of patients with myeloma, who were treated with IMiDs. These results collectively suggest that THBS-1 represents an endogenous substrate of cereblon. This pairing is disrupted by IMiDs, and the aberrant accumulation of THBS-1 plays an important role in the pathogenesis of IMiDs-induced thromboembolism.

    DOI: 10.1182/bloodadvances.2023010080

    Web of Science

    Scopus

    PubMed

  • GPAMを介したリゾホスファチジン酸合成は急性骨髄性白血病のミトコンドリア動態を制御する(GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia)

    Irifune Hidetoshi, Kochi Yu, Miyamoto Toshihiro, Sakoda Teppei, Kato Koji, Kunisaki Yuya, Akashi Koichi, Kikushige Yoshikane

    Cancer Science   114 ( 8 )   3247 - 3258   2023.8   ISSN:1347-9032

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    急性骨髄性白血病(AML)に特異的なミトコンドリア機能の制御に関与する分子メカニズムを検討した。CD34陽性AML細胞と健常な造血幹/前駆細胞を比較した代謝物スクリーニングを通じて、AMLにおけるリゾホスファチジン酸(LPA)合成活性の亢進を同定した。LPAは、LPA合成経路の律速酵素であるグリセロール-3-リン酸アシルトランスフェラーゼ(GPAT)によってグリセロール-3-リン酸から合成される。GPATの4つのアイソザイムのうち、グリセロール-3-リン酸アシルトランスフェラーゼ、ミトコンドリア(GPAM)がAML細胞で高発現していた。GPAMサイレンシングまたはFSG67(GPAM阻害剤)でLPA合成を阻害すると、ミトコンドリア分裂が誘導され、その結果、酸化的リン酸化が抑制され、活性酸素種が増加することで、AMLの増殖が著しく阻害された。さらに、FSG67によるGPAM阻害は、in vivoでの正常な造血に影響を与えることなく、AMLに対して有効であることが示された。以上より、GPAMを介したグリセロール-3-リン酸からのLPA合成経路は、AMLにおけるミトコンドリア動態を特異的に制御する重要な代謝機構であり、GPAMは有望な治療標的であることが示唆された。

  • GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia

    Irifune, H; Kochi, Y; Miyamoto, T; Sakoda, T; Kato, K; Kunisaki, Y; Akashi, K; Kikushige, Y

    CANCER SCIENCE   114 ( 8 )   3247 - 3258   2023.8   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:English   Publisher:Cancer Science  

    Metabolic alterations, especially in the mitochondria, play important roles in several kinds of cancers, including acute myeloid leukemia (AML). However, AML-specific molecular mechanisms that regulate mitochondrial dynamics remain elusive. Through the metabolite screening comparing CD34+ AML cells and healthy hematopoietic stem/progenitor cells, we identified enhanced lysophosphatidic acid (LPA) synthesis activity in AML. LPA is synthesized from glycerol-3-phosphate by glycerol-3-phosphate acyltransferases (GPATs), rate-limiting enzymes of the LPA synthesis pathway. Among the four isozymes of GPATs, glycerol-3-phosphate acyltransferases, mitochondrial (GPAM) was highly expressed in AML cells, and the inhibition of LPA synthesis by silencing GPAM or FSG67 (a GPAM-inhibitor) significantly impaired AML propagation through the induction of mitochondrial fission, resulting in the suppression of oxidative phosphorylation and the elevation of reactive oxygen species. Notably, inhibition of this metabolic synthesis pathway by FSG67 administration did not affect normal human hematopoiesis in vivo. Therefore, the GPAM-mediated LPA synthesis pathway from G3P represents a critical metabolic mechanism that specifically regulates mitochondrial dynamics in human AML, and GPAM is a promising potential therapeutic target.

    DOI: 10.1111/cas.15835

    Web of Science

    Scopus

    PubMed

  • Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function

    Kikushige, Y; Miyamoto, T; Kochi, Y; Semba, Y; Ohishi, M; Irifune, H; Hatakeyama, K; Kunisaki, Y; Sugio, T; Sakoda, T; Miyawaki, K; Kato, K; Soga, T; Akashi, K

    BLOOD ADVANCES   7 ( 14 )   3592 - 3603   2023.7   ISSN:2473-9529 eISSN:2473-9537

     More details

    Language:English   Publisher:Blood Advances  

    Cancer-specific metabolic activities play a crucial role in the pathogenesis of human malignancies. To investigate human acute leukemia–specific metabolic properties, we comprehensively measured the cellular metabolites within the CD34+ fraction of normal hematopoietic stem progenitor cells (HSPCs), primary human acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL) cells. Here, we show that human leukemia cells are addicted to the branched-chain amino acid (BCAA) metabolism to maintain their stemness, irrespective of myeloid or lymphoid types. Human primary acute leukemias had BCAA transporters for BCAA uptake, cellular BCAA, α-ketoglutarate (α-KG), and cytoplasmic BCAA transaminase-1 (BCAT1) at significantly higher levels than control HSPCs. Isotope-tracing experiments showed that in primary leukemia cells, BCAT1 actively catabolizes BCAA using α-KG into branched-chain α-ketoacids, whose metabolic processes provide leukemia cells with critical substrates for the trichloroacetic acid cycle and the synthesis of nonessential amino acids, both of which reproduce α-KG to maintain its cellular level. In xenogeneic transplantation experiments, deprivation of BCAA from daily diet strongly inhibited expansion, engraftment and self-renewal of human acute leukemia cells. Inhibition of BCAA catabolism in primary AML or ALL cells specifically inactivates the function of the polycomb repressive complex 2, an epigenetic regulator for stem cell signatures, by inhibiting the transcription of PRC components, such as zeste homolog 2 and embryonic ectoderm development. Accordingly, BCAA catabolism plays an important role in the maintenance of stemness in primary human AML and ALL, and molecules related to the BCAA metabolism pathway should be critical targets for acute leukemia treatment.

    DOI: 10.1182/bloodadvances.2022008242

    Web of Science

    Scopus

    PubMed

  • TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia

    Sakoda, T; Kikushige, Y; Miyamoto, T; Irifune, H; Harada, T; Hatakeyama, K; Kunisaki, Y; Kato, K; Akashi, K

    BLOOD ADVANCES   7 ( 10 )   2053 - 2065   2023.5   ISSN:2473-9529 eISSN:2473-9537

     More details

    Language:English   Publisher:Blood Advances  

    The activation of β-catenin plays critical roles in normal stem cell function, and, when aberrantly activated, the maintenance and enhancement of cancer stemness in many solid cancers. Aberrant β-catenin activation is also observed in acute myeloid leukemia (AML), and crucially contributes to self-renewal and propagation of leukemic stem cells (LSCs) regardless of mutations in contrast with such solid tumors. In this study, we showed that the AML-specific autocrine loop comprised of T-cell immunoglobulin mucin-3 (TIM-3) and its ligand, galectin-9 (Gal-9), drives the canonical Wnt pathway to stimulate self-renewal and propagation of LSCs, independent of Wnt ligands. Gal-9 ligation activates the cytoplasmic Src homology 2 domain of TIM-3 to recruit hematopoietic cell kinase (HCK), a Src family kinase highly expressed in LSCs but not in HSCs, and HCK phosphorylates p120-catenin to promote formation of the LDL receptor–related protein 6 (LRP6) signalosome, hijacking the canonical Wnt pathway. This TIM-3/HCK/p120-catenin axis is principally active in immature LSCs compared with TIM-3–expressed differentiated AML blasts and exhausted T cells. These data suggest that human AML LSCs constitutively activates β-catenin via autocrine TIM-3/HCK/p120-catenin signaling, and that molecules related to this signaling axis should be critical targets for selective eradication of LSCs without impairing normal HSCs.

    DOI: 10.1182/bloodadvances.2022008405

    Web of Science

    Scopus

    PubMed

  • TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia Reviewed International journal

    Sakoda T, Kikushige Y, Miyamoto T, Irifune H, Harada T, Hatakeyama K, Kunisaki Y, Kato K, Akashi K.

    Blood Advances   7 ( 10 )   2053 - 2065   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The activation of β-catenin plays critical roles in normal stem cell function, and, when aberrantly activated, the maintenance and enhancement of cancer stemness in many solid cancers. Aberrant β-catenin activation is also observed in acute myeloid leukemia (AML), and crucially contributes to self-renewal and propagation of leukemic stem cells (LSCs) regardless of mutations in contrast with such solid tumors. In this study, we showed that the AML-specific autocrine loop comprised of T-cell immunoglobulin mucin-3 (TIM-3) and its ligand, galectin-9 (Gal-9), drives the canonical Wnt pathway to stimulate self-renewal and propagation of LSCs, independent of Wnt ligands. Gal-9 ligation activates the cytoplasmic Src homology 2 domain of TIM-3 to recruit hematopoietic cell kinase (HCK), a Src family kinase highly expressed in LSCs but not in HSCs, and HCK phosphorylates p120-catenin to promote formation of the LDL receptor-related protein 6 (LRP6) signalosome, hijacking the canonical Wnt pathway. This TIM-3/HCK/p120-catenin axis is principally active in immature LSCs compared with TIM-3-expressed differentiated AML blasts and exhausted T cells. These data suggest that human AML LSCs constitutively activates β-catenin via autocrine TIM-3/HCK/p120-catenin signaling, and that molecules related to this signaling axis should be critical targets for selective eradication of LSCs without impairing normal HSCs.

    DOI: 10.1182/bloodadvances.2022008405.

  • Genomic analysis for TIM-3-expressing measurable residual disease post allogeneic SCT

    Sakoda Teppei

    Japanese Journal of Transplantation and Cellular Therapy   12 ( 3 )   167 - 171   2023   eISSN:2436455X

     More details

    Language:Japanese   Publisher:Japanese Society for Transplantation and Cellular Therapy  

    <p> The relapse of acute myeloid leukemia is a critical problem in clinics. As the prognosis of patients who relapse after allogeneic stem cell transplantation (allo-SCT) is poor, the evaluation of minimal/measurable residual disease (MRD) is crucial for determining the risk of relapse. Multiparameter flow cytometry (MFC) is an established method for quantifying MRD by European Leukemia Net. One of our primary concerns about MFC-MRD is its genetic backbone. In addition to MFC, detecting genetic abnormalities with next-generation sequencing (NGS) is a useful method for quantifying MRD. MFC-MRD and NGS-MRD are complementary approaches for predicting relapse, but conflicting results are observed in some cases. To determine the relevance of MFC-MRD and NGS-MRD, we performed single-cell targeted DNA and surface protein analysis using the Tapestri platform. Then, we established a heterogeneity characterized by the expression pattern of the surface antigen where populations with similar genetic background could produce different MRD statuses between MFC-MRD and NGS-MRD. Therefore, to track the residual disease responsible for relapse, we focused on T-cell immunoglobulin mucin-3 (TIM-3), a leukemic stem cell (LSC)-specific functional molecule. Furthermore, we demonstrated that the evaluation of TIM-3<sup>+</sup> LSCs could be useful in predicting relapses after allo-SCT.</p>

    DOI: 10.7889/tct-23-005

    CiNii Research

  • TIM-3 signaling hijacks the canonical Wnt/<i>β</i>-catenin pathway to maintain cancer stemness in human acute myeloid leukemia

    SAKODA Teppei, KIKUSHIGE Yoshikane

    Rinsho Ketsueki   64 ( 6 )   547 - 552   2023   ISSN:04851439 eISSN:18820824

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>Acute myeloid leukemia (AML) is one of the most common hematologic malignancies derived from self-renewing and highly propagating leukemic stem cells (LSCs). We have previously identified T-cell immunoglobulin mucin-3 (TIM-3) as an AML LSC-specific surface molecule by comparing the gene expression profiles of LSCs and hematopoietic stem cells (HSCs). TIM-3 expression clearly discriminates LSCs from HSCs within the CD34<sup>+</sup>CD38<sup>-</sup> stem cell fraction. Furthermore, AML cells secrete galectin-9 (Gal-9, a TIM-3 ligand) in an autocrine manner, resulting in constitutive TIM-3 signaling, which maintains LSC self-renewal capacity through <i>β</i>-catenin accumulation. In this study, we investigated the LSC-specific mechanisms of TIM-3 signaling. We found that TIM-3 signaling drove the canonical Wnt pathway, which was independent of Wnt ligands, to maintain cancer stemness in LSCs. Gal-9 ligation activated the cytoplasmic Src homology 2 (SH2) binding domain of TIM-3 to recruit hematopoietic cell kinase (HCK), a Src family kinase that is highly expressed in LSCs. HCK phosphorylated p120-catenin to promote the formation of the LDL receptor-related protein 6 (LRP6) signalosome, hijacking the canonical Wnt pathway. This TIM-3/HCK/p120-catenin axis was employed principally in immature LSCs compared to TIM-3-expressing exhausted T-cells.</p>

    DOI: 10.11406/rinketsu.64.547

    PubMed

    CiNii Research

  • Panuveitis induced by donor-derived CD8<sup>+</sup> T cells after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia

    Takeda A., Sakoda T., Yawata N., Kato K., Hasegawa E., Shima T., Hikita S., Yoshitomi K., Takenaka K., Oda Y., Akashi K., Sonoda K.H.

    American Journal of Ophthalmology Case Reports   27   101673   2022.9   ISSN:24519936

     More details

    Language:English   Publisher:American Journal of Ophthalmology Case Reports  

    Purpose: This article presents a case of panuveitis that occurred after unrelated allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with lymphoma-type human T-cell leukemia virus type-1 (HTLV-1)-associated adult T-cell leukemia (ATL). Observations: A 45-year-old man developed unilateral panuveitis 18 months after undergoing allo-HSCT. He underwent vitrectomy, and depositions of grey-white granules localized on the retinal artery were observed in the eye. Cytological examination of the vitreous aspirates showed that the atypical lymphoid cells stained positive for CD3 and CD8, but negative for CD4, B-cell markers, and cytomegalovirus antigen. Interphase fluorescence in situ hybridization using X‐ and Y‐chromosome probes revealed complete donor chimerism in CD8+ T cells in the vitreous aspirates. Conclusions and importance: Donor-derived CD8+ T lymphocytes can induce panuveitis like HTLV-1-assiciated uveitis after allo-HSCT in patients with ATL. Pathological diagnosis of vitreous infiltration by vitrectomy is helpful in patients with ATL. Donor-derived CD8+ T lymphocytes-induced panuveitis is recurrent but susceptible to regional corticosteroid treatment.

    DOI: 10.1016/j.ajoc.2022.101673

    Scopus

    PubMed

▼display all

Presentations

▼display all

MISC

  • 急性骨髄性白血病におけるTIM-3をマーカーとした同種移植後微小残存病変のゲノム解析

    迫田 哲平

    日本造血・免疫細胞療法学会雑誌   12 ( 3 )   167 - 171   2023.7

     More details

    Language:Japanese   Publisher:(一社)日本造血・免疫細胞療法学会  

    急性骨髄性白血病における同種移植後の再発は極めて予後不良であり,大きな臨床的課題である。この再発を早期に予測するためには,測定可能/微小残存病変(measurable/minimal residual disease,MRD)の定量的評価が有用である。European Leukemia Net(ELN)は,マルチパラメーターフローサイトメトリ(MFC)によるMRD評価法を確立した手法と定義しているが,遺伝子変異で定義されるMRDとの関係性や,同種移植後MRDを用いた予後予測法の最適化など明らかにすべき課題は依然として存在する。本稿では,細胞表面抗原によるMRDと遺伝子変異によるMRDの関係性を明らかにするためのシングルセル解析を用いたアプローチ,及び,本邦におけるMFC-MRD評価法の確立に向けたTIM-3を用いた微小残存白血病幹細胞評価法の有用性の検討について報告する。(著者抄録)

  • Precision medicine for AML/MDS 急性骨髄性白血病におけるTIM-3分子による白血病幹細胞性特異的canonical Wnt/β-catenin経路ハイジャック機構

    迫田 哲平, 菊繁 吉謙

    臨床血液   64 ( 6 )   547 - 552   2023.6   ISSN:0485-1439

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    ヒト急性骨髄性白血病(acute myeloid leukemia,AML)においては,一部の白血病幹細胞(leukemic stem cells,LSCs)のみが,自己複製能と白血病細胞への限定的分化能を有し白血病細胞集団を維持している。我々は先行研究において,ヒト正常造血幹細胞には発現せずにLSCsにのみ特異的に発現する表面抗原としてT-cell immunoglobulin mucin-3(TIM-3)を同定した。本研究においてヒトAMLにおいては,リガンドのTIM-3分子への結合により,Src family kinaseの一つであるHCKがTIM-3細胞質内ドメインと結合し活性化すること,HCKは基質としてp120-cateninをリン酸化することでWntリガンド非依存的に恒常的なcanonical Wnt pathwayの活性化を誘導することを明らかにした。(著者抄録)

Research Projects

  • Functional analysis of treatment-resistant leukemia stem cells and identification of molecular targets

    Grant number:25K02677  2025.4 - 2029.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    宮本 敏浩, 菊繁 吉謙, 迫田 哲平

      More details

    Grant type:Scientific research funding

    我々が同定した白血病幹細胞機能分子TIM-3の研究から、急性骨髄性白血病(AML)の発症時に認める白血病幹細胞(LSCs)と同様の細胞表面形質であるCD34+CD38-TIM-3+分画が、再発に寄与する白血病幹細胞であることを遺伝子変異解析および臨床的な予後予測解析から明らかにした。従来の幹細胞研究は診断時または再発時を想定して研究されてきたが、これまで直接的な解析が困難であったLSCsをTIM-3によって可視化することで、LSCsが生存維持のために特異的に依存する分子機構を解析し、残存潜伏LSCsを根絶するための基盤研究となることを目的とする。

  • 寛解期残存急性骨髄白血病幹細胞におけるCRHBPの機能の解明

    Grant number:24K11561  2024

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    迫田 哲平

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    急性骨髄性白血病(AML)再発メカニズムに重要な役割を果たす寛解期に残存する白血病幹細胞(LSC)に焦点を絞り、その潜伏するための分子機構を明らかにし、再発を防ぐための新規治療標的を見出すことを目標とする。既に我々は先行研究において、同一症例のLSCをTIM-3分子を用いて診断時、寛解期、再発期のそれぞれのフェーズの骨髄液から純化し、遺伝子変異に差がなくとも、寛解期の潜伏状態LSCは特徴的な遺伝子発現プロファイルを有していることを見出している。この知見を活かし、特に初発時(再発時)と比して寛解期LSCにおいて発現が上昇するCRHBP蛋白がAMLの潜伏において果たす役割について解析を行う。

    CiNii Research

  • 治療抵抗性残存急性骨髄性白血病幹細胞の寛解期における潜伏機構の解明

    Grant number:21K16269  2021 - 2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Early-Career Scientists

    迫田 哲平

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    CiNii Research

Class subject

  • 血液

    2023.10 - 2024.3   Second semester

Outline of Social Contribution and International Cooperation activities

  • 特記すべき活動は無い